According to multi-center cohort analysis, early IFN-α-2b administrations were linked to a decreased mortality rate in COVID-19 patients, but late administration was linked to a greater mortality rate and a delayed recovery [109]. This evidence concerns the gene IFNA2 and COVID-19.